|
Michael Becker, president and CEO of Cytogen Corporation (CYTO) and former New York City Mayor Rudy Giuliani, preside over the Market Open |
| |

Michael Becker, president and CEO of Cytogen Corporation (CYTO) and former New York City Mayor Rudy Giuliani, ring The NASDAQ Stock Market Opening Bell |
Michael Becker, president and CEO of Cytogen Corporation (CYTO) and former New York City Mayor Rudy Giuliani,
Ring The NASDAQ Stock Market Opening Bell
Friday, September 1, 2006
at NASDAQ's MarketSite
in New York City.

Cytogen Corporation [CYTO] |
| |
Additional Photographs & Reprint Permissions
Archived MarketSite Events | Summary Quote
Michael Becker, president and CEO of Cytogen Corporation (CYTO) and former New York City Mayor Rudy Giuliani preside over the opening bell to help kick off Prostate Cancer Awareness Month and the fifth annual "Screen, Stage and Support" campaign to promote prostate cancer education. "Screen, Stage and Support" is the annual awareness campaign sponsored by Cytogen to help patients, families and caregivers to recognize the important role that proper screening, diagnosis, treatment and support can have for anyone affected by prostate cancer.
Leading prostate cancer patient organizations joining in the opening bell ceremony are the American Cancer Society, the American Urological Association, the Prostate Cancer Foundation and UsTOO International.
Founded in 1980, Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company dedicated to improving the lives of patients with cancer by acquiring, developing and commercializing innovative molecules targeting the sites and stages of cancer progression.
Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection), PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide, and SOLTAMOX(TM) (tamoxifen citrate, oral solution 10mg/5mL) in the United States.
Cytogen's development pipeline consists of CYT-500, a therapeutic radiolabeled antibody targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Cytogen also has exclusive United States marketing rights to COMBIDEX(R)
(ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code 7228) for oncology applications in the United States. Full prescribing information for the Company's products is available at www.cytogen.com or by calling 800-833-3533. For more information, please visit the Company's website at www.cytogen.com
Reprints
Click for larger pictures of the NASDAQ MarketSite.
Additional Photographs for 9/1/2006
© Copyright 2006, The NASDAQ Stock Market, Inc.
Reprinted with the permission of The Nasdaq Stock Market, Inc. |
|